Imrie, C
While not all of these uses are proven (and some may never be), the fact that semaglutide is being investigated for so many different conditions is very exciting, especially for those with PMOS
Nat Rev Endocrinol 8:728742 Rosenstock J, Raccah D, Koranyi L et al (2013) Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)
We are also finding out that the impacts of GLP-1 agonists go beyond weight loss, manifesting in sometimes surprising ways
In fact, some researchers have suggested it may be selenium, not protein, that is responsible for increasing IGF-1
Ellman's reagent rapidly reacts with glutathione (Schmidt et al